Megan J. Penick

Megan Penick is a partner in M&R’s New York office. A general corporate and securities lawyer and business and corporate governance consultant, Megan brings more than 15 years of experience to her practice.

She is sought after for her work guiding private companies through the process of going public. Likewise, Megan is known for helping public companies meet their SEC filing and disclosure requirements. In addition, she represents issuers and underwriters in the sale of equity and debt securities, mergers and acquisitions, and corporate governance matters.

A niche area of Megan’s practice includes working with entrepreneurs, start-ups, and mid-sized ventures—both China-based and domestic—as outside general counsel, assisting these clients in all aspects of their corporate legal development. In this capacity, she handles a range of transactions, including those involving listing and uplisting issues (whether to NASDAQ or NYSE), as well as Regulation A+ offerings, the preparation and filing of quarterly and annual reports, proxy statements, current reports on Form 8-K, and registration statements. 

More particularly, Megan has represented a NASDAQ-listed company in China relative to a $15M registered direct offering; worked on behalf of other China-based corporations in completing reverse mergers into publicly-traded U.S. companies; and advised an oil and gas concern in China on NASDAQ listing, financing, and SEC-related matters. No doubt, her ability to communicate in Mandarin certainly came in handy in these transactions.

Domestically, Megan represents both private and NASDAQ-listed companies in the education, cannabis, biotech, and pharmaceutical spaces, among many others.

Representative Matters

Corporate Transactional: Represents NASDAQ-listed issuers in general corporate and securities matters.

Note Offering: Represented NASDAQ-listed education technology company relative to $22M note offering.

Private Placement: Represented wireless communications systems developer in connection with the private placement of $6M in common stock.

Private Placement: Represented pharmaceutical company in private placement of up to $10M in equity securities.

Public Offering: Represented NASDAQ-listed education technology company in $11.5M underwritten offering of its Class A Common Stock, pursuant to a registration statement on S-1.

Public Offering: Represented NASDAQ-listed education technology company in $34.5M underwritten public offering of its Class A Common Stock, pursuant to the take down of a shelf-registration statement on Form S-3.

Stock Offerings: Represented issuer in successful Regulation A+ offering of up to $50M of common stock.

Publications

Past Speaking Engagements

Blog Posts

• Corporate Risk Disclosures in the Wake of the 2020 Election
  February 27, 2021
• SEC Approves Amendments to Nasdaq and NYSE Continued Listing Requirements Due to the COVID-19 Pandemic
  April 24, 2020
• SEC Announces Temporary Regulatory Relief for Market Participants Affected by Coronavirus
  March 31, 2020
• SEC Relaxes Federal Proxy Rules for Annual Meetings
  March 24, 2020